Actionable news
All posts from Actionable news
Actionable news in FLML: Flamel Technologies S.A.,

Flamel Technologies to Report First Quarter 2016 Results

LYON, FRANCE, May 02, 2016 (Marketwired via COMTEX) -- Flamel Technologies FLML, +7.50% today announced that the Company will report its financial results for the first quarter ended March 31, 2016 on Monday, May 9, 2016, before the market open. A conference call to discuss these results has been scheduled for Monday, May 9, 2016 at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.

To participate in the conference call, investors are invited to dial 800-753-0420 (U.S. and Canada) or 913-312-0645 (international). The conference ID number is 3821495. A live audio webcast can be accessed by visiting the Investor section of the Company's website at A replay of the webcast will be archived on Flamel's website for 90 days following the event.

About Flamel Technologies: Flamel Technologies SA FLML, +7.50% is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently markets two previously Unapproved Marketed Drugs ("UMDs") in the United States, Bloxiverz(R) (neostigmine methylsulfate injection) and Vazculep(R) (phenylephrine hydrochloride injection). The Company also develops products utilizing its proprietary drug delivery platforms, Micropump(R) (oral sustained release microparticles platform), along with its tangent technologies, LiquiTime(R) (a Micropump-derivative platform for liquid oral products) and Trigger Lock(TM) (a Micropump-derivative platform for abuse-resistant opioids). Additionally, the Company has developed a long acting injectable platform, Medusa(TM), a hydrogel depot technology. Current applications of Flamel's drug delivery...